BofA analyst Tazeen Ahmad upgraded Rhythm Pharmaceuticals (RYTM) to Buy from Neutral.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Promising Phase 3 Results for Setmelanotide Boost Rhythm Pharmaceuticals’ Market Potential
- Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results
- Rhythm Pharmaceuticals says Phase 3 TRANSCEND trial meets primary endpoint
- Roku, Tesla among Q2 Tactical Ideas at Wells Fargo
- Strategic Positioning and Promising Trials Drive Buy Rating for Rhythm Pharmaceuticals